(4-bromophenyl)-(4'-fluoro-2'-methoxy-phenyl)-methanone

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (4-bromophenyl)-(4'-fluoro-2'-methoxy-phenyl)-methanone
• 化学式: C₁₄H₁₀BrFO₂
• 分子量: 309.135
• InChiKey: ZFYZPNGXELIUBK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.83
• 重原子数：
  18.0
• 可旋转键数：
  3.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  26.3
• 氢给体数：
  0.0
• 氢受体数：
  2.0

反应信息

• 作为产物：
  描述：

  间氟苯甲醚 、 4-溴苯甲酰氯 在 aluminum (III) chloride 作用下， 以 硝基苯 为溶剂， 以41.6%的产率得到(4-溴苯基)-(2-氟-4-甲氧基苯基)甲酮
  参考文献：
  名称：

  [EN] INDUCTION OF ESTROGEN RECEPTOR BETA BY CHOLESTEROL BIOSYNTHESIS INHIBITORS AND METHODS OF TREATMENT OF CANCER
  [FR] INDUCTION DU RÉCEPTEUR BÊTA DES OESTROGÈNES PAR DES INHIBITEURS DE LA BIOSYNTHÈSE DU CHOLESTÉROL ET MÉTHODES DE TRAITEMENT DU CANCER

  摘要：

  本文揭示了与发现胆固醇抑制剂在ERα阳性和ERα阴性乳腺癌细胞系，包括三阴性细胞中诱导抗增殖蛋白雌激素受体β（ERβ）相关的方法和组合物。

  公开号：

  WO2014004854A1

文献信息

• OXIDOSQUALENE CYCLASE AS A PROTEIN TARGET FOR ANTICANCER THERAPEUTICS
  申请人：Hyder Salman M.

  公开号：US20140005187A1

  公开（公告）日：2014-01-02

  The present invention identifies the cholesterol biosynthetic pathway, including the enzyme oxidosqualene cyclase, as new protein targets for anti-tumor therapeutics. The present invention further provides a class of oxidosqualene cyclase inhibitors containing a tertiary amine linked with aromatic ring structures, as a new class of anticancer agents. Compounds disclosed herein have been tested in 19 cell lines including breast cancer, prostate cancer, lung cancer (including drug-resistant lung cancer H69AR), colon cancer, ovarian cancer (including drug-resistant OVCAR-3), and pancreatic cancer cells, as wells as in human breast and prostate xenograft tumor growth in nude mice, and have been shown to be active.

  本发明确定了胆固醇生物合成途径，包括酶氧化齐墩果烷环化酶，作为抗肿瘤治疗的新蛋白靶点。本发明还提供了一类含有与芳香环结构相连的三级胺的氧化齐墩果烷环化酶抑制剂，作为一类新的抗癌剂。本文所披露的化合物已经在19种细胞系中进行了测试，包括乳腺癌、前列腺癌、肺癌（包括耐药性肺癌H69AR）、结肠癌、卵巢癌（包括耐药性OVCAR-3）和胰腺癌细胞，以及在裸鼠的人类乳腺和前列腺异种移植肿瘤生长中显示出活性。
• Oxidosqualene cyclase as a protein target for anticancer therapeutics
  申请人：Hyder Salman M.

  公开号：US10143686B2

  公开（公告）日：2018-12-04

  Disclosed herein is a new and improved therapy for the treatment of cancer, which comprises the step of altering cell membrane lipid composition by treating a cancer cell with an enzyme inhibitor which inhibits enzymes regulating the cholesterol biosynthetic pathway. One preferred protein target in the cholesterol biosynthetic pathway to inhibit is oxidosqualene cyclase. In some forms, inhibitors of one or more pathways are combined with an existing chemotherapeutic agent to combat drug resistance and enhance the therapeutic efficacy of conventional therapy.

  本文公开了一种用于治疗癌症的新型改良疗法，该疗法包括改变细胞膜脂质成分的步骤，即用一种酶抑制剂处理癌细胞，该酶抑制剂可抑制调节胆固醇生物合成途径的酶。胆固醇生物合成途径中的一个首选抑制蛋白靶点是氧化醌环化酶。在某些形式中，一种或多种途径的抑制剂与现有的化疗药物结合使用，以消除耐药性并提高传统疗法的疗效。
• INDUCTION OF ESTROGEN RECEPTOR BETA BY CHOLESTEROL BIOSYNTHESIS INHIBITORS AND METHODS OF TREATMENT OF CANCER
  申请人：The Curators Of The University Of Missouri

  公开号：EP2866810A1

  公开（公告）日：2015-05-06
• [EN] METHODS RELATED TO METABOLISM OF PARASITES AND MYCOBACTERIA<br/>[FR] METHODES RELATIVES AU METABOLISME DE PARASITES ET DE MYCOBACTERIES
  申请人：UNIV UTAH RES FOUND

  公开号：WO2000076316A1

  公开（公告）日：2000-12-21

  The present invention relates to the field of microorganism metabolism. In one aspect, the present invention relates to parasite and mycobacterial steroid compound biosynthesis, including methods to inhibit the steroid compound biosynthesis. The present invention therefore relates broadly to microbiology, pharmaceutical chemistery, and disease treatments.
• [EN] OXIDOSQUALENE CYCLASE AS A PROTEIN TARGET FOR ANTICANCER THERAPEUTICS<br/>[FR] OXYDOSQUALÈNE CYCLASE EN TANT QUE CIBLE PROTÉIQUE POUR DES PRODUITS THÉRAPEUTIQUES ANTICANCÉREUX
  申请人：UNIV MISSOURI

  公开号：WO2012092114A2

  公开（公告）日：2012-07-05

  The present invention identifies the cholesterol biosynthetic pathway, including the enzyme oxidosqualene cyclase, as new protein targets for anti-tumor therapeutics. The present invention further provides a class of oxidosqualene cyclase inhibitors containing a tertiary amine linked with aromatic ring structures, as a new class of anticancer agents. Compounds disclosed herein have been tested in 19 cell lines including breast cancer, prostate cancer, lung cancer (including drug-resistant lung cancer H69AR), colon cancer, ovarian cancer (including drug-resistant OVCAR-3), and pancreatic cancer cells, as wells as in human breast and prostate xenograft tumor growth in nude mice, and have been shown to be active.